P
PYC THERAPEUTICS LTD
ASX: PYC (PYC THERAP FPO [PYC])
Kemas kini terakhir: 4 jam lalu2.67
0.27 (11.25%)
| Penutupan Terdahulu | 2.40 |
| Jumlah Dagangan | 51,841,251 |
| Harga / Buku (P/B) | 3.79 |
| Julat 52 Minggu |
| Margin Keuntungan | -192.90% |
| Margin Operasi (TTM) | -225.50% |
| EPS Cair (TTM) | -0.110 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 32.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.17% |
| Nisbah Semasa (MRQ) | 5.46 |
| Aliran Tunai Operasi (OCF TTM) | -48.77 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -31.67 M |
| Pulangan Atas Aset (ROA TTM) | -58.01% |
| Pulangan Atas Ekuiti (ROE TTM) | -112.79% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (AU) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | PYC THERAP FPO [PYC] | - | - |
AISkor Stockmoo
0.3
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.33 |
|
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company’s drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 45.39% |
| % Dimiliki oleh Institusi | 0.97% |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |